Canakinumab

卡那奴单抗

Report date: 2026/05/14 20:00:28
First In Class

Base Information

Drug NameCanakinumab
Drug Alias NameCanakinumabum康纳单抗卡那吉努单抗卡那津单抗Ilaris +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsHyperimmunoglobulin D syndromeMuckle-Wells Syndrome (MWS)Coronavirus Disease 2019 (COVID-19) +[47] 
Global Approved IndicationsMuckle-Wells Syndrome (MWS)Cryopyrin-Associated Periodic Syndromes
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2009/06/17
Country/TerritoryCzechiaBelgiumBulgaria +[61] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesChildren'S National Research InstituteBroad Institute of MIT and HarvardYale University +[9] 
Inactive CompaniesRadboud University Medical CenterUniversity of ZurichCharite University, Berlin, Germany +[9] 
Active IndicationsHyperimmunoglobulin D syndromeMuckle-Wells Syndrome (MWS)Coronavirus Disease 2019 (COVID-19) +[23] 
Inactive IndicationsCognitive DysfunctionSchnitzler SyndromePrediabetic State +[24] 

Other Information

ATC CodeL04AC08
Related LinksWikipediaDrugBankKEGG